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Abstract
Introduction: Disturbance of the pro-coagulatant and anti-coagulant balance is associated with a poor outcome
from critical illness. The objective of this study is to determine whether the Factor V Leiden (FVL) mutation is
associated with susceptibility to or death from critical illness.
Methods: A genetic association study involving four case cohorts comprising two Gram negative sepsis, one
invasive pneumococcal disease and one intensive care unit cohort with a total of 1,249 patients. Controls were
derived from a population-based cohort study (N = 8,147). DNA from patients and controls was genotyped for the
FVL mutation.
Results: When all patients were investigated together no significant difference in the frequency of FVL mutation
was observed compared with controls (odds ratio (OR), 1.03; 95% confidence interval (CI), 0.83 to 1.29). However,
when stratified among patients admitted to intensive care (N = 237), susceptibility and the likelihood of long-term
death was influenced by the FVL mutation. In adjusted logistic regression analysis, FVL carriers had an increased
risk of ICU admission compared to non-carriers (OR 1.62; 95% CI, 1.08 to 2.42). In adjusted Cox regression analysis,
FVL carriers were at increased risk of long-term death compared to non-carriers (relative risk 1.78; 95% CI, 1.13 to
2.81). FVL carrier status did not predict either susceptibility to or outcome from Gram negative, Escherichia coli or
Streptococcus pneumoniae sepsis.
Conclusions: Overall, the FVL mutation did not appear to increase the risk of admission due to severe invasive
infections. Nevertheless, in the subgroup of patients admitted to intensive care an increased risk and a poorer
long-term outcome for individuals with critical illness were observed for FVL mutation carriers.
Introduction
Critical illness associated with sepsis and the systemic
inflammatory response syndrome (SIRS) is an important
cause of morbidity and mortality [1-3]. In recent years,
a growing number of discoveries have identified the
importance of host genetic factors in SIRS and sepsis
outcomes [4].
One human genetic factor that may be involved is fac-
tor V but its role is controversial. A single non-synon-
ymous amino acid substitution (Arg506Gln) in factor V,
the factor V Leiden (FVL) mutation, causes resistance to
activated protein C (APC) leading to increased levels of
thrombin [5]. The FVL mutation per se is associated
with an increased risk of thromboembolism [6,7].
Clinical and experimental studies that have investi-
gated the effect of the FVL mutation on sepsis outcomes
have come to conflicting conclusions. In one clinical
trial, FVL carriers with severe sepsis had a survival bene-
fit compared to non-carriers [8]. Similarly, FVL carriage
appeared to be associated with improved short-term
survival from the acute respiratory distress syndrome
(ARDS) [9]. Findings from one experimental endotoxe-
mia model supported this [8]. Other studies have found
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In an observational cohort, the FVL mutation did not
affect survival from severe sepsis [10]. Genetically engi-
neered mouse models of peritonitis and group A strep-
tococcal (GAS) disease showed increased mortality from
sepsis and an increased susceptibility to GAS infection
[11,12]. In meningococcal disease, FVL carriage was
associated with increased morbidity [13] and in sepsis
with a four-fold increased relative risk of mortality [14].
In the latter study, susceptibility to different manifesta-
tions of infectious diseases was also influenced by FVL
carriage.
The aim of the present study was to study the possible
association of FVL with critical illness caused by sepsis
and SIRS. To this end, we genotyped five cohorts
including individuals without infection, individuals with
SIRS and individuals with sepsis caused by Gram nega-
tive bacteria and Streptococcus pneumoniae. The allele
and carrier frequencies were analyzed for association
with susceptibility to infection and outcome from
infection.
Materials and methods
Cohorts
Control group
All subjects who participated in the 1991 to 1994
Copenhagen City Heart Study (CCHS) were included in
the control group if they had not had an infectious dis-
ease hospitalization by 31 December 2001 or a case of
invasive pneumococcal disease (IPD) by 1 October 2007.
Subjects ≥ 20 years old were selected randomly after age
stratification from among residents of Copenhagen. Of
the 17,180 individuals invited, 10,135 participated, 9,259
provided blood samples, and 9,253 were genotyped for
factor V Leiden. A total of 1,106 individuals were
excluded because they had been hospitalized at least
once with an infectious disease. Thus, a total of 8,147
adults comprised the control group. Ninety-nine percent
were of Danish decent [15]. Details of study procedures
have been described elsewhere [6]. All subjects provided
written, informed consent, and the ethics committee for
Copenhagen and Frederiksberg approved the study
(Record no. 100.2039/91).
Gram negative sepsis cohort 1 (G1)
There were 452 consecutive episodes of Gram negative
bacteremia among 427 individuals admitted to Hvidovre
Hospital from June 2000 through May 2002. Of these,
319 were a first episode of bacteremia during the study
period and had DNA collected. None of the patients
were lost to follow-up. Ninety-five percent were of Dan-
ish decent. Details of the study are described elsewhere
[16]. The study was approved by the Ethics Committee
for Copenhagen and Frederiksberg counties (record no.
01-085/2000).
Gram negative sepsis cohort 2 (G2)
All patients older than 18 years admitted to Amager
Hospital, Bispebjerg Hospital, Frederiksberg Hospital or
Hvidovre Hospital in Copenhagen from January 2003
through May 2005 with a positive blood and urine cul-
ture yielding Escherichia coli were included in the study.
A total of 575 consecutive episodes of E. coli bacteremia
with bacturia were included. None of the patients were
lost to follow-up. The study was approved by the Ethics
Committee for Copenhagen and Frederiksberg counties
(record no. 01-2006-6173).
Intensive care unit (ICU) cohort
From February 1998 to July 1999, 272 individuals
admitted to the academic, multidisciplinary ICU at
Glostrup Hospital, who met the criteria for SIRS, as out-
l i n e db yB o n ee ta l .[ 1 7 ] ,w e r ei n c l u d e di nt h es t u d y .
Respiratory failure requiring intubation is generally
required for ICU admission in Denmark. All individuals
in this cohort were intubated and mechanically venti-
lated. Details are described elsewhere [18]. Informed
consent was obtained from all patients or from their
close relatives. The study was approved by the local
ethics committee for Copenhagen County (record no.
KA 96097).
Invasive pneumococcal disease (IPD) cohort
Two studies contributed cases to the IPD cohort. In the
1991 to 1994 CCHS, cases (N = 52; 44 with FV geno-
type) were identified through linkage with the National
Streptococci Reference laboratory (NSR), Statens Serum
Institut [19]. From 141 adults included in a study of
mannan-binding lectin (MBL) genotypes and IPD, 119
had DNA available for FV genotyping [20]. In total, the
IPD cohort comprised 163 individuals. Informed consent
was obtained from all patients. The study was approved
by Ethics Committee for Copenhagen and Frederiksberg
Counties (record no. H-KF-01-152/99).
Factor V genotypes
Genomic DNA was extracted and stored at -20°C. The
FVL mutation (Arg506Gln) was identified by one of
three methods. Restriction fragment length polymorph-
ism PCR was used for the CCHS control group, G1 and
IPD cohort as described [6,21,22]. Light Cycler techno-
logy (Roche, Basel, Switzerland) was used to determine
the FVL genotype in the G2 cohort as described [23].
The ICU cohort was genotyped with the TaqMan
MGB method. In brief, single-nucleotide variants
were detected using Taq Man MGB probe assay
(C__11975250_10, TaqMan® MGB assay, Applied Bio-
systems, Foster City, CA, USA) according to the manu-
facturer’s instructions. Four controls were added for
every 44 reactions: two allelic controls (one homozygous
for the minor allele and one heterozygous; major/minor)
and two non-template controls. PCR was performed
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and 40× (15 sec 92°C, 1 minute 60°C). Results were ana-
lyzed on ABI PRISM 7700 Sequence Detection platform
using the SDS software v1.9 (Applied Biosystems), and
using the allele discrimination plate read function to
detect the end-point fluorescence in each well. Genotype
results were manually assigned. Sanger-sequencing was
applied to two randomly chosen patients on each plate
(ABI Prism 3100 Genetic Analyser, Applied Biosystems).
Statistics
Genotype distributions were tested for Hardy-Weinberg
equilibrium by using c
2 tests. Allele, genotype, carrier fre-
quency and demographic features were evaluated by using
c
2 or Fisher exact tests, whenever appropriate. We calcu-
lated odds ratios (ORs) and 95% confidence intervals (CI)
when appropriate. Multiple logistic regression analysis was
done to evaluate the association between FVL and sus-
ceptibility to infection after adjusting for age and sex.
In survival analysis, heterozygous and homozygous
individuals were combined (carriers) and compared with
noncarriers. Cox regression analysis examined time to
death by using hazard ratios (HR) with 95% CIs. Covari-
ates that were associated with death in univariate analy-
sis were included in the multivariate model. Short-term
survival was defined as outcome at Day 30 after admis-
sion for infection or critical illness. Long-term outcome
was defined survival status at the end of follow up. Sta-
tistical analysis was performed with SPSS 17.0 (Statisti-
cal Package for Social Sciences, Chicago, IL, USA). We
considered two-tailed P values of < 0.05 to be statisti-
cally significant.
Results
The genotype distribution did not differ from that pre-
dicted by Hardy-Weinberg equilibrium for any of the
five cohorts (P > 0.2 for all). Characteristics of subjects
in each cohort are shown in Table 1. When all patients
were investigated together no significant difference in
the frequency of FVL mutation was observed compared
with controls (OR 1.03; 95% CI, 0.83 to 1.29).
Intensive care unit cohort
From the ICU cohort, 237 individuals (87%) had DNA
available for analysis. Individuals excluded because DNA
was unavailable were significantly younger (57 vs. 64
years, P = 0.006) than individuals included but did not
differ with respect to sex or markers of disease severity
at baseline. Overall the ICU cohort was slightly younger
and had more males than the control cohort (Table 1).
Using c
2 statistics to compare allele and genotype fre-
quencies we found that patients admitted to the ICU
more often were carriers of the A allele and the GA
genotype compared to controls. After adjustment for
age and sex, the odds ratios correlating to the A allele
and GA genotype with ICU admission remained statisti-
cally significant (1.66 (1.11 to 2.4) and 1.62 (1.08 to
2.42), respectively; Table 2).
Short-term mortality rates were higher among carriers
admitted to the ICU than non-carriers but the difference
was not statistically significantly different (Table 3).
However, long-term survival was affected by FVL carrier
status. During a median of 698 (IQR: 24 to 1117) days
of follow up, 23 of 28 (82.1%) carriers compared to 115
of 209 (55%) non-carriers died (log-rank test, P =0 . 0 0 5 ,
Figure 1). In multivariate analysis, adjusting for factors
that were associated with outcome in univariate analysis,
FVL carrier status, age and SAPS II score at baseline
were associated with long-term outcome (Table 4).
Other cohorts
FVL carrier status did not predict either susceptibility to
or outcome from Gram negative sepsis, E. coli sepsis, S.
pneumonia sepsis or the combined case cohort (Tables
2 and 3).
Discussion
Our findings suggest that a genetic disposition to coagu-
lation, FVL, may be associated with susceptibility to and
outcome from critical illness.
The present study and its findings add to a growing
number of studies in apparent disagreement. However,
the published studies are not immediately comparable.
T h ea n i m a lm o d e l su s e dt r a n s g e n i cm i c eb u to t h e r w i s e
differed in their approach and in their findings. Kerlin et
al. used injectable lipopolysaccharide (LPS) from E. coli
to elicit sepsis and showed that FVL was associated with
improved survival [8]. Sun et al. induced sepsis through
subcutaneous injection of GAS and showed a marked
relationship between the FV deficiency and increased
Table 1 Characteristics of the five cohorts
Controls
N = 8147
All cases
N = 1249
ICU cohort
N = 237
G1 cohort
N = 315
G2 cohort
N = 534
IPD cohort
N = 163
Age, yrs
Median (IQR)
66 (54 to 76) 74 (61 to 83)* 64 (52 to 73)* 76 (61 to 84)* 78 (68 to 86)* 69 (56 to 78)
Female, % 55.7 55.2 48.5* 54 59.6 52.8
*, P < 0.05 compared to control group (Mann-Whitney’s or Fisher’s exact test). IQR: interquartile range; ICU: intensive care unit; G1: Gram negative sepsis cohort 1;
G2: Gram negative sepsis cohort 2; IPD: invasive pneumococcal disease.
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and puncture method to induce sepsis and showed that
FVL was disadvantageous for short-term survival [11].
The five clinical studies also differ significantly. Two
showed a beneficial effect, two a detrimental effect of
FVL carriage, and one showed no effect of FVL carriage
on outcome from severe sepsis [8-10,13,14]. Kerlin et al.
applied a post hoc analysis to a randomized clinical trial
(RCT) of adult patients with severe sepsis in whom FVL
was beneficial for short-term survival. Although, this
study is closest to our ICU population, a RCT repre-
sents a selected population eligible to study specified
inclusion criteria, and, thus, may be subject to selection
bias [8]. Adamzik et al. included individuals admitted to
intensive care who had ARDS [9]. FVL was associated
with improved short-term survival in patients with
ARDS but, although the majority also had an infection
(pneumonia or sepsis), ARDS represents a distinct
population with a different disease entity. Kondaveeti et
al. studied children who had meningococcal disease and
showed an association between FVL and disease severity
but not to outcome [13]. The study size, however, had
limited statistical power tod e t e c tad i f f e r e n c ei no u t -
come because the mortality rate was low. Our own
study relied on hospital discharge records and included
a limited number of individuals hospitalized with sepsis
[14]. Nevertheless, the detrimental effect of the FVL
mutation was striking. Thus, the published studies are
based on heterogeneous patient populations and the dif-
ferences between them emphasize the need for more
research in this area.
The increased risk of critical illness associated with
FVL carriage is not immediately explained. FVL leads to
greater risk of thromboembolism and confers resistance
to APC [6]. Treatment with APC has been shown to
improve survival from severe sepsis [24]. The mechan-
isms responsible for the benefit of APC are unknown but
believed to derive from APC’s anti-inflammatory and
anti-coagulation properties. We speculate that individuals
with FVL have reduced intrinsic anti-inflammatory
Table 2 Factor V allele and genotype frequencies in individuals with systemic inflammatory response syndromeand
sepsis compared to controls
Controls
N = 8147
All cases
N = 1249
ICU cohort
N = 237
G1 cohort
N = 315
G2 cohort
N = 534
IPD cohort
N = 163
Number and frequency
of the FV alleles (%)
G
A
15648 (96.0)
646 (4.0)
2396 (95.9)
102 (4.1)
446 (94.1)
28 (5.9)
607 (96.3)
23 (3.7)
1025 (95.9)
43 (4.0)
318 (97.5)
8 (2.5)
Allele P value – Chi Sq = 0.0517;
df = 1; P = 0.820
Chi.Sq = 4.0156;
df = 1; P = 0.0451
Chi.Sq = 0.0856;
df = 1; P = 0.7699
Chi.Sq = 0.004;
df = 1; P = 0.984
Chi.Sq = 1.5506;
df = 1; P = 0.2131
OR (95% CI) – 1.03 (0.83 to 1.28) 1.52 (1.03 to 2.25) 0.97 (0.63 to 1.49) 0.92 (0.65 to 1.30) 0.63 (0.31 to 1.30)
Adj. OR (95% CI)* – 1.02 (0.82 to 1.29) 1.66 (1.11 to 2.49) 0.97 (0.63 to 1.50) 0.92 (0.65 to 1.30) 0.63 (0.31 to 1.30)
Allelic P value** – 0.871 0.014 0.897 0.626 0.216
Number and frequency
of the FV genotype (%)
GG 7518 (92.3) 1150 (92.1) 209 (88.2) 292 (92.7) 494 (92.5) 155 (95.1)
GA 612 (7.5) 96 (7.7) 28 (11.8) 23 (7.3) 37 (6.9) 8 (4.9)
AA 17 (0.2) 3 (0.2) 0 0 3 (0.6) 0
Genotypic P value – 0.952 0.04 0.71 0.3 0.23
OR (95% CI)***
Carrier vs. non-carrier
– 1.03 (0.83 to 1.28) 1.60 (1.07 to 2.39) 0.94 (0.61 to 1.45) 0.97 (0.69 to 1.35) 0.62 (0.30 to 1.26)
Adj. OR (95% CI)*
Carrier vs. non-carrier
– 1.03 (0.83 to 1.29) 1.62 (1.08 to 2.42) 0.95 (0.61 to 1.46) 0.97 (0.69 to 1.36) 0.62 (0.30 to 1.27)
Genotypic P value** – 0.791 0.019 0.799 0.847 0.189
*: Adjusted for age and sex. **: adjusted analysis. ***: logistic regression analysis of carriers (GA or AA) vs. non-carriers. CI, confidence interval; OR, Odds ratio. ICU:
intensive care unit; G1: Gram negative sepsis cohort 1; G2: Gram negative sepsis cohort 2; IPD: invasive pneumococcal disease.
Table 3 Mortality rates associated with Factor V carrier
status in individuals with critical illness
Mortality
30-day 90-day Overall
ICU cohort
Non-carrier 55/209 (26.3) 72/209 (34.4) 115/209 (55)
Carrier 11/28 (39.3) 14/28 (50) 23/28 (82.1)*
G1 cohort
Non-carrier 40/292 (13.7) 70/294 (24) 90/292 (30.8)
Carrier 5/23 (21.7) 8/23 (34.8) 8/23 (34.8)
G2 cohort
Non-carrier 80/494 (16.2) 113/494 (22.9) 275/494 (56.0)
Carrier 10/40 (25.0) 11/40 (27.5) 21/40 (52.5)
IPD cohort
Non-carrier 24/155 (15.5) NA NA
Carrier 1/8 (12.5)
*: Fisher’s exact test P = 0.007. ICU: intensive care unit; G1: Gram negative
sepsis cohort 1; G2: Gram negative sepsis cohort 2; IPD: invasive
pneumococcal disease.
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bances of the pro- and anti-coagulant balance leading to
microthrombolism. Vasodilation and microthrombolism
in combination likely impair blood circulation and
accentuate the effects of sepsis.
FVL affected long-term survival from critical illness. It
is unclear what may explain this correlation. One expla-
nation may be that critical illness altered the comorbid
risk profile of patients after discharge. Smeeth et al.
have shown that acute lower respiratory tract infections
and urinary tract infections are associated with a transi-
ent increase in the risk of a vascular event (myocardial
infarction, stroke and venous thromboembolism)
[25,26]. The mechanisms by which acute inflammation
may affect the risk of vascular events are uncertain but
may include endothelial dysfunction. Since FVL is asso-
ciated with an increased risk of thromboembolism per
se it is possible that sepsis and SIRS induced inflamma-
tion further increased the risk of a vascular event after
an admission to intensive care for critical illness. Unfor-
tunately, we are unable to investigate this in more detail
because our study does not include information on spe-
cific causes of death after discharge from hospital.
Future studies are warranted to further investigate this
association.
Our study has several limitations. Individuals in the
case cohorts were either younger or older than indivi-
duals in the control cohort. This may influence the
estimates of disease susceptibility because age is one of
the most important risk factors for acquisition of
infectious disease. However, the effects of Factor V
Leiden carrier status did not change significantly when
age was included or omitted from the logistic regres-
sion analysis.
Ethnicity was unknown in three of the five cohorts.
Population stratification may lead to findings that are
due to the underlying structure of the population and
not the genetic variation being studied. However, we
find it unlikely that population stratification has affected
our results. In the two cohorts with known ethnic back-
ground 99% and 95% of individuals were of Danish
decent. The remaining three cohorts were recruited
from similar populations in the same geographical area
as the cohorts with known ethnic backgrounds.
Figure 1 Survival after admission to intensive care among carriers and non-carriers of the factor V Leiden mutation.
Table 4 Multivariate analysis of factors associated with
long-term mortality after ICU admission
Univariate
analysis
HR (95%)
Multivariate
analysis
HR (95%)
P
value
FVL
Non-carrier 1.0 1.0
Carrier 1.88 (1.20 to 2.95) 1.78 (1.13 to 2.81) 0.013
Age
(per year
increment)
1.04 (1.03 to 1.05) 1.02 (1.01 to 1.03) 0.002
SAPS II
(per point
increment)
1.05 (1.04 to 1.06) 1.03 (1.02 to 1.05) 0.0001
FVL, Factor V Leiden; HR, hazard ratio; SAPS II, Simplified acute physiology
score II.
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approval of activated protein C (APC) for treatment of
severe sepsis. However, cohort G2 and, in part, the IPD
cohort were established after 2002. In theory, use of
APC could modulate the effect of the Factor V Leiden
mutation. Information on APC use in these two cohorts
was unavailable but a very limited number of individuals
in all of Denmark received APC during the study period
(the average number of APC treatments in Denmark
between 2004 and 2008 were 20 per year). Thus, it
appears unlikely that use of APC affected our results.
The sample size was small to moderate for the four dis-
ease cohorts. Consequently, the study may have had
insufficient statistical power to detect small and moder-
ate associations between FVL carrier status and disease
or disease outcome.
Conclusions
Overall, the FVL mutation did not appear to increase
the risk of admission due to severe invasive infections
and was not associated with overall outcome. However,
the present study suggests that the FVL mutation may
increase the susceptibility to critical illness and may
confer a poor long-term outcome of critical illness.
Key messages
￿ The FVL mutation was significantly associated with
an increased risk of admission to intensive care.
￿ The FVL mutation was significantly associated with
an increased risk of long-term mortality after admis-
sion to intensive care.
￿ The FVL mutation was not associated with an
increased risk of severe invasive infections.
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